236 related articles for article (PubMed ID: 33994183)
21. Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: Impact of national programme of antifungal prophylaxis.
Czyżewski K; Gałązka P; Frączkiewicz J; Salamonowicz M; Szmydki-Baran A; Zając-Spychała O; Gryniewicz-Kwiatkowska O; Zalas-Więcek P; Chełmecka-Wiktorczyk L; Irga-Jaworska N; Bień E; Ociepa T; Wawryków P; Tomaszewska R; Płonowski M; Pierlejewski F; Gamrot-Pyka Z; Małas Z; Urbanek-Dądela A; Stolpa W; Zaucha-Prażmo A; Goździk J; Chaber R; Gil L; Styczyński J
Mycoses; 2019 Nov; 62(11):990-998. PubMed ID: 31429997
[TBL] [Abstract][Full Text] [Related]
22. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology of invasive fungal disease in haematologic patients.
Souza L; Nouér SA; Morales H; Simões B; Solza C; Queiroz-Telles F; Nucci M
Mycoses; 2021 Mar; 64(3):252-256. PubMed ID: 33141969
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation.
Linke C; Ehlert K; Ahlmann M; Fröhlich B; Mohring D; Burkhardt B; Rössig C; Groll AH
Mycoses; 2020 Feb; 63(2):172-180. PubMed ID: 31661569
[TBL] [Abstract][Full Text] [Related]
25. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study.
Kuster S; Stampf S; Gerber B; Baettig V; Weisser M; Gerull S; Medinger M; Passweg J; Schanz U; Garzoni C; Berger C; Chalandon Y; Mueller NJ; van Delden C; Neofytos D; Khanna N;
Transpl Infect Dis; 2018 Dec; 20(6):e12981. PubMed ID: 30144374
[TBL] [Abstract][Full Text] [Related]
26. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.
Döring M; Blume O; Haufe S; Hartmann U; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2014 Apr; 33(4):629-38. PubMed ID: 24173819
[TBL] [Abstract][Full Text] [Related]
27. The clinical management of invasive mold infection in children with cancer or undergoing hematopoietic stem cell transplantation.
Lehrnbecher T
Expert Rev Anti Infect Ther; 2019 Jul; 17(7):489-499. PubMed ID: 31149864
[No Abstract] [Full Text] [Related]
28. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
29. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
Dvorak CC; Fisher BT; Esbenshade AJ; Nieder ML; Alexander S; Steinbach WJ; Dang H; Villaluna D; Chen L; Skeens M; Zaoutis TE; Sung L
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):417-425. PubMed ID: 33136159
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center.
Linke C; Tragiannidis A; Ahlmann M; Fröhlich B; Wältermann M; Burkhardt B; Rossig C; Groll AH
Mycoses; 2019 Oct; 62(10):954-960. PubMed ID: 31332851
[TBL] [Abstract][Full Text] [Related]
31. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
32. Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study.
Jin H; Fan Z; Huang F; Chai Y; Xuan L; Lin R; Xu N; Ye J; Sun J; Liu Q
Infection; 2019 Apr; 47(2):275-284. PubMed ID: 30734248
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
Omer AK; Ziakas PD; Anagnostou T; Coughlin E; Kourkoumpetis T; McAfee SL; Dey BR; Attar E; Chen YB; Spitzer TR; Mylonakis E; Ballen KK
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1190-6. PubMed ID: 23747459
[TBL] [Abstract][Full Text] [Related]
35. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
Vehreschild JJ; Sieniawski M; Reuter S; Arenz D; Reichert D; Maertens J; Böhme A; Silling G; Martino R; Maschmeyer G; Rüping MJ; Ullmann AJ; Cornely OA
Int J Antimicrob Agents; 2009 Nov; 34(5):446-50. PubMed ID: 19700265
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
[TBL] [Abstract][Full Text] [Related]
38. Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5-year retrospective study.
Li Y; Liu M; Zhai B; Zhao X; Wang L; Li H; Wang S; Zhu H; Wang Q; Gao C; Huang W; Yu L
Intern Med J; 2018 Jun; 48(6):713-720. PubMed ID: 29230923
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
[TBL] [Abstract][Full Text] [Related]
40. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.
Lehrnbecher T; Fisher BT; Phillips B; Beauchemin M; Carlesse F; Castagnola E; Duong N; Dupuis LL; Fioravantti V; Groll AH; Haeusler GM; Roilides E; Science M; Steinbach WJ; Tissing W; Warris A; Patel P; Robinson PD; Sung L
J Clin Oncol; 2020 Sep; 38(27):3205-3216. PubMed ID: 32459599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
